Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- Pujade-Lauraine, Eric
- Ledermann, Jonathan A
- Selle, Frédéric
- Gebski, Val
- Penson, Richard T
- Oza, Amit M
- Korach, Jacob
- Huzarski, Tomasz
- Poveda, Andrés
- Pignata, Sandro
- Friedlander, Michael
- Colombo, Nicoletta
- Harter, Philipp
- Fujiwara, Keiichi
- Ray-Coquard, Isabelle
- Banerjee, Susana
- Liu, Joyce
- Lowe, Elizabeth S
- Bloomfield, Ralph
- Pautier, Patricia
- Vergote, Ignace
Publication date
September 2017
DOI Publisher
Elsevier BV Journal
The Lancet OncologyAbstract
Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients with platinum-sensitive, relapsed high-grade serous ovarian cancer. We aimed to confirm these findings in patients with a BRCA1 or BRCA2 (BRCA1/2) mutation using a tablet formulation of olaparib.status: publishe
Add to ORKG